Cortex Sells Selected AMPAKINE Compounds And Rights To Respiratory Depression Indication To Biovail (Medical News Today)

Cortex Pharmaceuticals, Inc. (OTCBB: CORX) announced that it has entered into an agreement with Biovail Laboratories International SRL (”Biovail”) in which Biovail acquired certain AMPAKINE compounds and the rights to the patent filing for respiratory depression and vaso-occlusive crises associated with sickle cell disease. The transaction with Biovail includes a purchase price of $10,000,000 …

See the rest here:
Cortex Sells Selected AMPAKINE Compounds And Rights To Respiratory Depression Indication To Biovail (Medical News Today)

Related posts:

1. Biovail acquires Ampakine compounds from Cortex Pharma for respiratory depression treatment (PharmaBiz)
2. Researchers identify risk factors for major depression in elderly patients (News-Medical-Net)
3. Trends: From Anxiety To Depression And Back Again (Medical News Today)
4. Depression As Deadly As Smoking, But Anxiety May Be Good For You (Medical News Today)
5. Journal highlights debate over collective depression syndrome among asylum-seeking detainees (News-Medical-Net)